(CIDRAP News) The US Food and Drug Administration (FDA) has approved a high-dose seasonal influenza vaccine for elderly people, whose aging immune systems may not respond effectively to flu vaccines intended for younger people.
The vaccine, Fluzone High-Dose, made by Sanofi Pasteur, contains four times as much antigen (active ingredient) as standard seasonal flu vaccines. The FDA and the company announced its approval Dec 23.
(CIDRAP News) Infection with H1N1 influenza poses a grave danger to pregnant women and those who have just delivered, and the risk increases when they do not receive antiviral treatment very rapidly, California and Atlanta researchers report today online ahead of print in the New England Journal of Medicine.
"This pandemic has the potential to notably increase overall maternal mortality in the United States in 2009," they write.
(CIDRAP News) The nation's supply of pandemic vaccine has grown to 111 million doses, enough so that the US Centers for Disease Control and Prevention (CDC) is turning part of its attention toward boosting the percentage of adults who get vaccinated.
(CIDRAP News) MedImmune Inc. today announced a recall of leftover doses from 13 lots of its nasal-spray H1N1 vaccine because of a slight loss of potency, but the company said those who received doses from the affected lots don't need to be revaccinated.
The company and the US Food and Drug Administration (FDA) said there are no safety problems with the recalled doses.
(CIDRAP News) Egypt's health ministry has confirmed an H5N1 avian influenza infection in a 21-year-old woman, the country's third case since late September, the World Health Organization (WHO) reported today.